Jing-ru Pang
State Key Laboratory Of Metabolic Dysregulation & Prevention And Treatment Of Esophageal Cancer, Key Laboratory Of Advanced Drug Preparation Technologies, Ministry Of Education, Key Laboratory Of Henan Province For Small Molecule Drug Discovery And Application
Zhengzhou, 450001, China
Zhengzhou, 450001, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Multiple gastric cancer tissue proteomic identification predicts CLU as a biomarker for anti-PD-1 immunotherapy.
Journal: Journal of pharmaceutical analysis
Published: September 07, 2025
Decoding CLU (Clusterin): Conquering cancer treatment resistance and immunological barriers.
Journal: International immunopharmacology
Published: April 25, 2024
Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer.
Journal: International journal of biological macromolecules
Published: March 22, 2023
Identification of the upstream regulators of KDM5B in gastric cancer.
Journal: Life sciences
Published: January 20, 2022
LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.
Journal: Molecular cancer
Published: January 10, 2022
Generation, secretion and degradation of cancer immunotherapy target PD-L1.
Journal: Cellular and molecular life sciences : CMLS
Published: November 21, 2021
Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Journal: European journal of medicinal chemistry
Published: September 09, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026